How big is Springworks Therapeutics, Inc.?

As of Jun 18, Springworks Therapeutics, Inc. has a market capitalization of $3.53 billion, with net sales of $219.67 million and a net profit loss of $253.94 million over the latest four quarters. The company's balance sheet shows shareholder's funds of $481.10 million and total assets of $587.28 million.

As of Jun 18, Springworks Therapeutics, Inc. has a market capitalization of 3,530.85 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 219.67 million for the latest four quarters. However, it also experienced a net profit loss of 253.94 million during the same period.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of 481.10 million and total assets amounting to 587.28 million.

What does Springworks Therapeutics, Inc. do?

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and cancer. As of March 2025, it reported net sales of $49 million and a net loss of $83 million, with a market cap of approximately $3.53 billion.

Overview: <BR>Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing medicines for patients suffering from rare diseases and cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 49 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -83 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3,530.85 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.69 <BR>Return on Equity: -59.66% <BR>Price to Book: 8.46<BR><BR>Contact Details: <BR>Address: 100 Washington Blvd, STAMFORD CT: 06902-9302 <BR>Tel: 1 203 8839490 <BR>Fax: 1 302 6555049 <BR>Website: https://www.springworkstx.com/

Should I buy, sell or hold Springworks Therapeutics, Inc.?

Who are in the management team of Springworks Therapeutics, Inc.?

As of March 2022, the management team of Springworks Therapeutics, Inc. includes Mr. Daniel Lynch (Independent Chairman), Mr. Saqib Islam (CEO and Director), and Dr. Stephen Squinto (Acting Head of R&D and Director), along with Independent Directors Mr. Alan Fuhrman, Dr. Freda Lewis-Hall, and Mr. Jeffrey Schwartz.

As of March 2022, the management team of Springworks Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Daniel Lynch, who serves as the Independent Chairman of the Board.<BR>- Mr. Saqib Islam, the Chief Executive Officer and a Director.<BR>- Dr. Stephen Squinto, the Acting Head of Research and Development and a Director.<BR><BR>Additionally, the Board of Directors features Independent Directors: Mr. Alan Fuhrman, Dr. Freda Lewis-Hall, and Mr. Jeffrey Schwartz.

Is Springworks Therapeutics, Inc. overvalued or undervalued?

As of February 27, 2024, Springworks Therapeutics, Inc. is considered risky and overvalued due to high financial metrics like a Price to Book Value of 8.45 and negative returns on capital and equity, despite a year-to-date stock performance of 30.06% that exceeds the S&P 500's return.

As of 27 February 2024, the valuation grade for Springworks Therapeutics, Inc. has moved from does not qualify to risky. The company appears to be overvalued based on its financial metrics, particularly given its high Price to Book Value of 8.45 and negative EV to EBITDA of -12.42. Additionally, the negative ROCE of -201.75% and ROE of -59.66% further indicate significant financial distress compared to its peers.<BR><BR>In the peer comparison, Springworks Therapeutics has a P/E ratio of -14.1396, while Biohaven Ltd. and Neumora Therapeutics, Inc. do not qualify for a P/E ratio, highlighting the relative riskiness of Springworks. The company’s recent stock performance shows a year-to-date return of 30.06%, which outpaces the S&P 500's return of 12.22%, suggesting some market optimism despite the underlying valuation concerns. Overall, Springworks Therapeutics is considered overvalued in the current market context.

Is Springworks Therapeutics, Inc. technically bullish or bearish?

As of June 23, 2025, Springworks Therapeutics, Inc. shows a mildly bullish trend, supported by a bullish daily moving average and weekly RSI, despite mixed signals from the MACD and Dow Theory, while outperforming the S&P 500 with a year-to-date return of 30.06%.

As of 23 June 2025, the technical trend for Springworks Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish daily moving average and a bullish weekly RSI. However, the weekly MACD and KST are mildly bearish, indicating some caution. The Dow Theory shows a bearish signal on both weekly and monthly timeframes, which adds to the mixed signals. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 30.06% compared to 12.22% for the index, and over one year, it returned 26.08% against the S&P's 17.14%.